Ann: ACW presents at Sachs Neuro & WHO grants INN emestedastat, page-3

this investor conference could also push up the stock price to may be 3 cents - whether that triggers another cap raise on the basis of interest rates kind of being sluggish is the unknown - I know they say we should have enough but they may have external pressure to do so. This would dilute again and the price months before the fomo to engage in the outcome of trial announcement will may be see it bounce again. The next question is how low it will go before a run up to announcement of interim trial results and this may be disappointing as they may only comment on safety. I have a small holding now and took a loss to reposition - I may come back in as it trades down in the next 3-4 months or there is another cap raise at a discount. If I look at some of the AI predictors it is a downward shift in the short and medium term and the volumes of trade are very low so interest in reality is low. Whether you take funds out and put to work somewhere else is the question and then come back in. I still like the story, but the waiting game is an opportunity cost.